Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Esophageal Squamous Cell Carcinoma
Conditions
Esophageal Squamous Cell Carcinoma
Trial Timeline
Mar 27, 2025 → Nov 1, 2029
NCT ID
NCT06644781About Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)
Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl) is a phase 3 stage product being developed by Daiichi Sankyo for Esophageal Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06644781. Target conditions include Esophageal Squamous Cell Carcinoma.
What happened to similar drugs?
19 of 20 similar drugs in Esophageal Squamous Cell Carcinoma were approved
Approved (19) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06644781 | Phase 3 | Recruiting |
Competing Products
20 competing products in Esophageal Squamous Cell Carcinoma